Anti-epidermal growth factor receptor (EGFR) agents, including cetuximab and panitumumab, in combination with chemotherapy, may also improve the survival of CRC patients with wild-type RAS tumors, but are ineffective in CRC tumors containing RAS mutations [15,17,22,23,24]. Here, EGFR is linked to colorectal carcinoma.